Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Ocuphire Pharma, Inc. | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 4, 2011
Rexahn Pharmaceuticals, Inc.
(Exact Name of Issuer as Specified in Charter)
|
DELAWARE
|
001-34079
|
11-3516358
|
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
|
15245 Shady Grove Road, Suite 455
|
20850
|
|
|
Rockville, MD
|
(Zip Code)
|
|
|
(Address of Principal Executive Offices)
|
(240) 268-5300
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
|
|
Item 8.01
|
Other Events.
|
On November 4, 2011, Rexahn Pharmaceuticals, Inc. (the “Company”) announced results from its Phase IIb clinical trial of Serdaxin® in major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 mg and 5 mg, to a placebo dose over an 8-week treatment period. Results from the study did not demonstrate Serdaxin’s efficacy compared to the placebo measured by the Montgomery-Asberg Depression Rating Scale (MADRS). All groups showed an approximate -14 point improvement in the protocol defined primary endpoint of MADRS. All groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. The study showed Serdaxin to be safe and well tolerated.
The Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
Number
|
Description
|
||
|
Press release dated November 4, 2011.
|
|||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Rexahn Pharmaceuticals, Inc. | |||
|
Date: November 4, 2011
|
By:
|
/s/ Tae Heum Jeong | |
| Name: Tae Heum Jeong | |||
| Title: Chief Financial Officer | |||